secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2026-09-15T13:06:12+00:00
Accession:  0001628280-26-061978
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz completes $820M upfront acquisition of Actio Biosciences for KCNT1 epilepsy drug ABS-1230
--------------------------------------------------------------------------------

- Jazz completed $820M upfront acquisition of Actio Biosciences; Actio now a wholly-owned subsidiary.
- ABS-1230 is a first-in-class oral KCNT1 inhibitor; inhibited all evaluable mutations in preclinical studies.
- In early clinical proof-of-concept, children with KCNT1-related epilepsy had meaningful seizure reductions.
- FDA granted Fast Track, Rare Pediatric Disease and Orphan Drug designations for ABS-1230.
- Actio spun off non-ABS-1230 programs into a new company; Jazz received a minority stake.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000162828026061978/0001628280-26-061978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000162828026061978/jazz-20260915.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-061978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer